Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

10.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.2K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

1.4K
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
1.4K
Bioavailability Study Design: Absolute Versus Relative Bioavailability01:27

Bioavailability Study Design: Absolute Versus Relative Bioavailability

315
Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
315
Bioavailability: Overview01:17

Bioavailability: Overview

385
Bioavailability refers to the proportion of an administered drug that reaches the systemic circulation in its active, unaltered form. It is a crucial pharmacokinetic parameter that determines the effectiveness of a drug in achieving its intended therapeutic outcomes. The route of administration significantly influences bioavailability, with intravenous administration achieving 100% bioavailability as the drug directly enters the bloodstream. In contrast, oral administration often results in...
385
Bioavailability: Overview01:13

Bioavailability: Overview

4.2K
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
4.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular insights into the anti-COVID-19 activity of reduced (quinol) and oxidized (quinone) forms of coenzyme Q10.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same author

Genistein and the immune system: experimental evidence, key challenges, and future perspectives.

Biochemical pharmacology·2026
Same author

Kavain for health promotion and disease mitigation: Pharmacological promise and therapeutic perspectives.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2026
Same author

HOXA9 orchestrates EMT and metastasis in oral cancer via transcriptional activation of vimentin and β-catenin signaling.

Cell death & disease·2026
Same author

The therapeutic potential of jaceosidin: a comprehensive review of its effects on chronic diseases.

Immunopharmacology and immunotoxicology·2026
Same author

Correction: Harnessing nanomedicine to target NFκB signalling in cancer: at the intersection of inflammatory signalling, metabolic reprogramming, and therapeutic innovation.

Cell communication and signaling : CCS·2026

Related Experiment Video

Updated: Jan 21, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.2K

Is curcumin bioavailability a problem in humans: lessons from clinical trials.

Ajaikumar B Kunnumakkara1, Choudhary Harsha1, Kishore Banik1

  • 1Cancer Biology Laboratory and DBT-AIST International Laboratory for Advanced Biomedicine (DAILAB), Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati , Guwahati , India.

Expert Opinion on Drug Metabolism & Toxicology
|July 31, 2019
PubMed
Summary

Turmeric

Keywords:
Turmericanti-inflammatoryantioxidantbioavailabilitychronic diseasescurcumin

More Related Videos

Labeling and Imaging of Amyloid Plaques in Brain Tissue Using the Natural Polyphenol Curcumin
10:15

Labeling and Imaging of Amyloid Plaques in Brain Tissue Using the Natural Polyphenol Curcumin

Published on: November 1, 2019

13.3K
Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

7.3K

Related Experiment Videos

Last Updated: Jan 21, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.2K
Labeling and Imaging of Amyloid Plaques in Brain Tissue Using the Natural Polyphenol Curcumin
10:15

Labeling and Imaging of Amyloid Plaques in Brain Tissue Using the Natural Polyphenol Curcumin

Published on: November 1, 2019

13.3K
Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

7.3K

Area of Science:

  • Nutraceutical science
  • Pharmacology
  • Integrative medicine

Background:

  • Turmeric, containing curcumin, has a long history in traditional medicine.
  • Curcumin shows promise in numerous in vitro, in vivo, and clinical studies for chronic diseases.
  • Concerns exist regarding curcumin's bioavailability, potentially limiting its therapeutic application.

Purpose of the Study:

  • To review over 200 clinical studies on curcumin's efficacy for various chronic diseases.
  • To explore strategies for enhancing curcumin bioavailability, including combinations and formulations.
  • To assess whether bioavailability issues impede curcumin's therapeutic potential.

Main Methods:

  • Systematic review of over 200 clinical studies involving curcumin.
  • Analysis of studies investigating curcumin's role in cardiovascular, inflammatory, metabolic, neurological, and oncological diseases.
  • Examination of research on combined therapies and novel curcumin formulations.

Main Results:

  • Curcumin demonstrates significant protective effects across a wide spectrum of chronic diseases.
  • Enhanced bioavailability was achieved through higher non-toxic doses, combination therapies, and advanced formulations.
  • Clinical evidence supports curcumin's efficacy, challenging bioavailability as a significant limitation.

Conclusions:

  • Curcumin's therapeutic potential in chronic diseases is well-supported by clinical trials.
  • Bioavailability concerns are mitigated by optimized dosing, combinations, and formulations.
  • Curcumin is a safe, cost-effective, and potent nutraceutical for managing chronic conditions.